Ukko Secures $40 Million in Series B Funding Led by Leaps by Bayer to Overcome Food Allergies and Sensitivities

Top industry leaders and venture firms unite behind Ukko's efforts to eliminate the world's most prevalent food allergies and sensitivities, including peanuts and gluten PALO ALTO, Calif., TEL AVIV, Israel and LEVERKUSEN, Germany, Jan. 27, 2021 -- (Heal... Biopharmaceuticals, Venture Capital Ukko, Bayer, food allergy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news